Thai Decision On Revised CL Policy To Be Ready By April
This article was originally published in PharmAsia News
While debate continues over Thailand's decision to continue its compulsory licensing practice, the Health Ministry expects a final decision to be ready by April. Minister Chaiya Sasomsap, who stirred the controversy by saying the CL policy of the previous administration would continue in place during a policy review, asked for a two-week extension of the deadline in light of the continuing international conflict over the practice. Four cancer drugs by foreign drug makers are at the core of the CL policy. (Click here for more
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.